IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Kelleher Financial Advisors

Kelleher Financial Advisors trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 27.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,625 shares of the medical research company’s stock after selling 997 shares during the quarter. Kelleher Financial Advisors’ holdings in IQVIA were worth $516,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. FMR LLC lifted its holdings in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the last quarter. Impax Asset Management Group plc lifted its holdings in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after buying an additional 157,809 shares during the last quarter. Legal & General Group Plc lifted its holdings in IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock worth $320,170,000 after buying an additional 11,715 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IQV. Evercore ISI decreased their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft reduced their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. The Goldman Sachs Group reduced their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Stephens started coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Stock Performance

NYSE IQV opened at $205.37 on Thursday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The business’s 50 day moving average is $199.53 and its two-hundred day moving average is $221.30. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The stock has a market capitalization of $37.27 billion, a price-to-earnings ratio of 26.95, a PEG ratio of 2.14 and a beta of 1.48.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.